2022 加拿大国家指南:浸润性乳腺癌的新辅助治疗

2022-02-28 国外肿瘤科相关专家小组(统称) Breast Cancer Res Treat

乳腺癌新辅助治疗(NABC)是一个快速变化的领域,来自加拿大的专家小组制定了涵盖乳腺癌整个新辅助治疗过程的循证指导建议。重点内容包括早期三阴性和HER2阳性乳腺癌的新辅助治疗以及残留几百患者的后续辅助

中文标题:

2022 加拿大国家指南:浸润性乳腺癌的新辅助治疗

英文标题:

A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles

发布日期:

2022-02-28

简要介绍:

乳腺癌新辅助治疗(NABC)是一个快速变化的领域,来自加拿大的专家小组制定了涵盖乳腺癌整个新辅助治疗过程的循证指导建议。重点内容包括早期三阴性和HER2阳性乳腺癌的新辅助治疗以及残留几百患者的后续辅助治疗,还涉及患者评估、系统治疗和局部治疗原则。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2022 加拿大国家指南:浸润性乳腺癌的新辅助治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d0a631c0023e0850, title=2022 加拿大国家指南:浸润性乳腺癌的新辅助治疗, enTitle=A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles, guiderFrom=Breast Cancer Res Treat, authorId=0, author=, summary=乳腺癌新辅助治疗(NABC)是一个快速变化的领域,来自加拿大的专家小组制定了涵盖乳腺癌整个新辅助治疗过程的循证指导建议。重点内容包括早期三阴性和HER2阳性乳腺癌的新辅助治疗以及残留几百患者的后续辅助, cover=https://img.medsci.cn/202231/1646110843905_1608702.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Mon Feb 28 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">乳腺癌新辅助治疗(NABC)是一个快速变化的领域,来自加拿大的专家小组制定了涵盖乳腺癌整个新辅助治疗过程的循证指导建议。重点内容包括早期三阴性和HER2阳性乳腺癌的新辅助治疗以及残留几百患者的后续辅助治疗,还涉及患者评估、系统治疗和局部治疗原则。</span></p>, tagList=[TagDto(tagId=13575, tagName=浸润性乳腺癌), TagDto(tagId=117297, tagName=妇瘤乳腺肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=6, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3653, appHits=96, showAppHits=0, pcHits=392, showPcHits=3556, likes=0, shares=36, comments=3, approvalStatus=1, publishedTime=Tue Mar 01 15:46:00 CST 2022, publishedTimeString=2022-02-28, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Tue Mar 01 13:01:16 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Thu Jan 04 15:59:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 加拿大国家指南:浸润性乳腺癌的新辅助治疗.pdf)])
2022 加拿大国家指南:浸润性乳腺癌的新辅助治疗.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1200790, encodeId=16341200e9018, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Mar 09 08:32:09 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199251, encodeId=8f421199251d7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Fri Mar 04 03:48:45 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198726, encodeId=cd821198e26a1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d025566392, createdName=ms4000000158650782, createdTime=Wed Mar 02 14:57:57 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-09 ms9000001873897494

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1200790, encodeId=16341200e9018, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Mar 09 08:32:09 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199251, encodeId=8f421199251d7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Fri Mar 04 03:48:45 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198726, encodeId=cd821198e26a1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d025566392, createdName=ms4000000158650782, createdTime=Wed Mar 02 14:57:57 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-04 jing0309

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1200790, encodeId=16341200e9018, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Mar 09 08:32:09 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199251, encodeId=8f421199251d7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Fri Mar 04 03:48:45 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198726, encodeId=cd821198e26a1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d025566392, createdName=ms4000000158650782, createdTime=Wed Mar 02 14:57:57 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-02 ms4000000158650782

    学习一下

    0